Hereditary gastric cancer: what ’s new? Update 2013–2018

AbstractAround 10 –20% of gastric cancer patients have relatives with a diagnosis of GC and in 1–3% of patients a genetic cause can be confirmed. Histopathologically, GC is classified into intestinal-type, with glandular growth, and diffuse-type with poorly cohesive growth pattern often with signet ring cells. Fa milial or hereditary GC is classified into hereditary diffuse GC (HDGC), familial intestinal GC (FIGC) and polyposis forms. This review focuses on recent research findings and new concepts of hereditary GC.
Source: Familial Cancer - Category: Cancer & Oncology Source Type: research

Related Links:

AbstractThe standard treatment for locally advanced gastric cancer differs across the world. In western countries, perioperative chemotherapy or postoperative adjuvant chemoradiotherapy are the preferred treatment options, whereas in Asia, D2 gastrectomy followed by postoperative adjuvant chemotherapy is standard. In Japan, adjuvant chemotherapy with S-1 is the standard treatment for pStage II gastric cancer, whereas adjuvant chemotherapy with a doublet regimen is preferred for pStage III gastric cancer. The efficacy of preoperative neoadjuvant chemotherapy using S-1 plus cisplatin, has been investigated in selected patien...
Source: Surgery Today - Category: Surgery Source Type: research
AbstractStaged esophagectomy was developed in the mid-twentieth century in an attempt to reduce high rates of postoperative morbidity and mortality. Nowadays, the operation has almost been abandoned due to its significant disadvantages, especially the need for multiple surgeries, inability of patients to feed between operations, and morbidity of esophageal stoma. However, staged esophagectomy is still occasionally useful for very high-risk patients and in particular cases, for example multiple cancers of the aerodigestive tract and emergent esophagectomy. Staged esophagectomy is based on the division of surgical stress int...
Source: Surgery Today - Category: Surgery Source Type: research
British Journal of Cancer, Published online: 14 October 2019; doi:10.1038/s41416-019-0600-9In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Publication date: 15 November 2019Source: Life Sciences, Volume 237Author(s): Heresh Moridi, Jamshid Karimi, Heidar Tavilani, Iraj Khodadadi, Amir Nader Emami RazaviAbstractAimsLong non-coding RNAs (LncRNAs) play central roles in the formation and development of gastric cancer (GC). The aim of this study was to evaluate the expression of PURPL and NONHSAT062994 and the relationship between their expressions with clinical characteristics in GC.Main methodsPURPL and NONHSAT062994 LncRNAs and p53 gene expression levels were analyzed both in 50 pairs of cancerous and adjacent noncancerous tissue samples in GC patients using qR...
Source: Life Sciences - Category: Biology Source Type: research
STOMACH cancer outcomes will greatly depend on the how far the cancer the has spread. It is therefore imperative to know the warning signs and get them checked out as soon as possible.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
As one of the most frequent chemical modifications in eukaryotic mRNAs, N6-methyladenosine (m6A) modification exerts important effects on mRNA stability, splicing, and translation. Recently, the regulatory rol...
Source: Molecular Cancer - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
ConclusionsAdjuvant therapy is associated with improved OS for patients with gastric GISTs>10cm but provides no benefit in OS for those with GISTs 2-10cm.
Source: The American Journal of Surgery - Category: Surgery Source Type: research
Authors: Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group &Review Panel Abstract [This corrects the article on p. 1 in vol. 19, PMID: 30944757.]. PMID: 31598379 [PubMed - in process]
Source: Journal of Gastric Cancer - Category: Gastroenterology Tags: J Gastric Cancer Source Type: research
We report a case of a 37-year-old man with a history of recurrent episodes of vomiting and long-standing type 2 diabetes mellitus. Esophagogastroduodenoscopy did not reveal any findings of reflux esophagitis or obstructive lesions. A gastric emptying time scan showed prolonged gastric emptying half-time (344 minutes) indicating delayed gastric emptying. Laboratory tests revealed elevated fasting serum glucose and glycosylated hemoglobin (HbA1c, 12.9%) and normal fasting C-peptide and insulin levels. We performed Roux-en-Y reconstruction after subtotal gastrectomy to treat gastroparesis and improve glycemic control, and the...
Source: Journal of Gastric Cancer - Category: Gastroenterology Tags: J Gastric Cancer Source Type: research
This study evaluated the safety and feasibility of MBBT in patients undergoing TLDG. Thirty-three patients who underwent TLDG with MBBT were retrospectively evaluated. The mean operation time was 277.6±37.1 minutes, including 51.9±15.7 minutes for reconstruction. Two patients had anastomosis-related complications, one patient with stricture after leakage and 1 patient with stenosis. The former patient was treated with endoscopic balloon dilatation, and the latter was managed conservatively; neither required re-operation. MBBT is a safe and feasible technique, with acceptable surgical outcomes. It may be a goo...
Source: Journal of Gastric Cancer - Category: Gastroenterology Tags: J Gastric Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | Genetics